Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a product name.
BioCentury | Mar 30, 2023
Politics, Policy & Law
Federal judge’s ruling could reduce access to cancer screening, HIV prevention drugs
Appeal of Texas judge’s ruling on ACA expected
BioCentury | Dec 16, 2022
Finance
Dec. 15 Quick Takes: Enlaza debuts with $61M, covalent targeting biologics platform
Plus: MinervaX taking strep vaccine to Phase II and updates from AbbVie, Prothena, Astria, Guardant and more
BioCentury | Mar 6, 2021
Management Tracks
Winter to lead BeiGene’s European commerical ops; plus Dyne, Axcella, Prometheus and more
BeiGene Ltd. (NASDAQ:BGNE; HKEX:6160) hired Gerwin Winter as SVP and head of commercial for Europe. Winter was previously SVP and head of Europe at Portola Pharmaceuticals Inc. before its acquisition
BioCentury | Oct 28, 2020
Deals
Thrive takeout could herald consolidation trend for early cancer detection companies
Exact Sciences’ $2.2B acquisition of Thrive closely followed Illumina’s $8B takeout of Grail; could a Roche buyout of Freenome be next?
BioCentury | Oct 8, 2020
Product Development
Mapping opportunities for China’s early cancer detection boom
How Chinese companies developing liquid biopsies for cancer are approaching the potentially massive market
BioCentury | Aug 27, 2020
Product Development
Freenome maps path forward for blood-based cancer screenings with $270M C round
Company expanding pivotal trial as it assesses next indications
BioCentury | Jun 29, 2019
Finance
Biotech backs down in 2Q19
Biotech stocks are down across the board in 2Q19 after 1Q19 gains
BioCentury | Oct 6, 2018
Finance
Large cap comeback
Biotech’s large caps led the way in 3Q18 for first time in past six quarters
Items per page:
1 - 10 of 105